Tempus AI Inc. (TEM)

NASDAQ: TEM · Real-Time Price · USD

52.61

0.94 (1.82%)

At close: May 01, 2025, 12:01 PM

1.82% (1D)

Bid	52.6
Market Cap	8.84B
Revenue (ttm)	693.4M
Net Income (ttm)	-705.81M
EPS (ttm)	-6.23
PE Ratio (ttm)	-8.44
Forward PE	258.75
Analyst	Buy

Ask	52.67
Volume	4,316,060
Avg. Volume (20D)	13,306,473
Open	53.50
Previous Close	51.67
Day's Range	51.54 - 54.31
52-Week Range	22.89 - 91.45
Beta	7.76

About TEM

Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-iden...

Sector Healthcare

IPO Date Mar 28, 2012

Employees 2,400

Stock Exchange NASDAQ

Ticker Symbol TEM

Website https://www.tempus.com

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 14.05% from the latest price.

Stock Forecasts

Why Price Moved

1 week ago

+14.62%

Tempus AI shares are trading higher after the comp... Unlock content with Pro Subscription

2 months ago

+5.35%

Shares of AI and tech stocks are trading higher ahead of Nvidia's earnings. The sector may also be rising following Supermicro's quarterly report filing.

News

Just now · businesswire.com

Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its su...

1 day ago · businesswire.com

Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Anal...

3 days ago · zacks.com

Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings?

TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up.

2 days ago · businesswire.com

Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-foc...

5 days ago · businesswire.com

Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including on...

1 week ago · zacks.com

Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?

Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN and Pathos AI. The multi-year deal focuses on building a multimodal AI-drive...

6 days ago · businesswire.com

Tempus to Report First Quarter 2025 Financial Results on May 6

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on...

1 week ago · fool.com

Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now?

Amid a bullish backdrop for the broader market, Tempus AI (TEM 17.72%) stock is posting big gains Wednesday. The company's share price was up 15.8% as of 1:45 p.m.

1 week ago · 247wallst.com

Discover Why Quantum Computing Stocks Are Soaring Today

With the stock market in rally mode, there are more pockets of strength than there have been in a while.

1 week ago · proactiveinvestors.com

Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos

Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop what it called the largest multimodal foundation model i...

Load More News